Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms (Video)

Data presented at the 2017 American Society of Hematology Annual Meeting support mutated calreticulin (CALR) as an MPN-specific tumor antigen, paving the way for immunotherapies targeting this mutation for patients with MPN.

 Cancer Network

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.